C12Y 201/01113
Site-specific dna-methyltransferase
Official title: Site-specific DNA-methyltransferase (cytosine-N4-specific) (2.1.1.113)
C12Y201/01113 (Site-specific dna-methyltransferase) appears on 3 US grants and 5 published applications in this corpus.
Search patents in C12Y- Granted patents
- 3
- Published applications
- 5
- Assignees
- 3
- Inventors
- 18
- Latest grant
- 7 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 1 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 3 |
| 2025 | 0 | 0 |
| 2026 | 2 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for the targeting of PCSK97 Apr 2026US 12,594,349 B2Scribe Therapeutics Inc.
- Compositions and methods for the targeting of PCSK917 Feb 2026US 12,551,573 B2Scribe Therapeutics Inc.
- Method for cloning and expression of StuI restriction endonuclease and StuI methylase in E. coli15 Nov 2011US 8,058,029 B2New England Biolabs, Inc.
- Compositions and methods for treating bacterial disease29 Jan 2026US 2026/0027191 A1Arizona Board of Regents on Behalf of the University of Arizona
- Method of modulating pcsk9 and uses thereof12 Dec 2024US 2024/0408236 A1
- Compositions and methods for the targeting of pcsk918 Apr 2024US 2024/0123089 A1Scribe Therapeutics Inc.
- Compositions and methods for the targeting of pcsk918 Apr 2024US 2024/0124537 A1Scribe Therapeutics Inc.
- Method for cloning and expression of stui restriction endonuclease and stui methylase in e. coli29 Jan 2009US 2009/0029418 A1New England Biolabs, Inc.
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.